JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, P.
Right arrow Articles by Walkinshaw, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, P.
Right arrow Articles by Walkinshaw, M. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 35, 24901-24905, August 27, 1999


Novel Mechanism of Inhibition of Elastase by beta -Lactams Is Defined by Two Inhibitor Crystal Complexes*

Paul Taylor, Violet Anderson, James DowdenDagger , Sabine L. FlitschDagger , Nicholas J. TurnerDagger , Karen Loughran§, and Malcolm D. Walkinshaw

From the Structural Biochemistry Group and The Edinburgh Centre for Protein Technology, Institute of Cell and Molecular Biology, The University of Edinburgh, Michael Swann Building, King's Buildings, Mayfield Road, Edinburgh EH9 3JR, United Kingdom, Dagger  Department of Chemistry and The Edinburgh Centre for Protein Technology, The University of Edinburgh, King's Buildings, West Mains Road, Edinburgh EH9 3JJ, United Kingdom, and § Nycomed Amersham plc, White Lion Road, Amersham HP7 9LL, Great Britain

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Two structurally related beta -lactams form different covalent complexes upon reaction with porcine elastase. The high resolution x-ray structures of these two complexes provide a clear insight into the mechanism of the reaction and suggest the design of a new class of serine protease inhibitors that resist enzyme reactivation by hydrolysis of the acyl intermediate. The presence of a hydroxyethyl substituent on the beta -lactam ring provides a new reaction pathway resulting in the elimination of the hydroxyethyl group and the formation of a stabilizing conjugated double bond system. In contrast, the presence of a diethyl substituent on the beta -lactam ring leads to addition of water. The two enzyme complexes show very different binding modes in the enzyme active site.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

beta -Lactam-related compounds are well established irreversible inhibitors of a wide range of serine proteases including elastase (1), beta -lactamase (2), phospholipase A2 (3), and bacterial signal peptidases (4). Moreover, their efficacy as orally active inhibitors has led to their widespread use in the clinic. In all cases a first step in the inhibition process is acylation of the active site serine by the beta -lactam ring to generate a covalently bound acyl-enzyme intermediate. Thereafter, the inhibitor may undergo a further fragmentation resulting in a more stable entity that is resistant to deacylation and hence regeneration of enzyme activity. In this study, we report the discovery of a novel mode of action of a class of monocyclic beta -lactams, which results in a particularly stable acyl-enzyme intermediate. The proposed mechanism, which is based on the x-ray structures of the elastase-ligand complexes presented below, may be generally applicable to other related serine proteases.

Human leukocyte elastase is an important therapeutic target in view of its implied role in diseases such as emphysema (5), cystic fibrosis (6), and rheumatoid arthritis (7). Two x-ray structures of beta -lactams bound to porcine pancreatic elastase (PPE)1 have been reported, the first involving a cephalosporin sulfone (8) and more recently an N-sulfonylaryl beta -lactam (9). In the latter case, the monocyclic beta -lactam simply acylates the active site serine residue without further fragmentation. The class of monocyclic beta -lactams reported herein contain an aryloxy substituent at the C-4 position (Fig. 1) that departs subsequent to acylation of the serine residue. We have compared two related members of this class of beta -lactam that differ primarily in the nature of the C-3 substituent. This difference results in distinct modes of action upon reaction with elastase.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   a and b, structures of EI116 and JD261 and the proposed mechanisms for their interaction with elastase. The structures of the starting ligands are given at the top of the figure. The middle panel shows likely covalently bound intermediates in which the beta -lactam ring is cleaved and the OAr group on C-4 has left. The bottom panel shows the formulae of the stable complexes as determined in the two x-ray structures.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The crystals were grown by the hanging drop method at room temperature. Porcine pancreatic elastase at 10 mg/ml was incubated with a 3-fold molar excess of inhibitor for 1.5 h at room temperature before drops were laid. The well solution contained 0.1 M sodium acetate buffer at pH 5.1 and 55 mM sodium sulfate. The drops consisted of 2 µl of protein and 2 µl of well solution. Crystals of approximate dimensions 0.5 × 0.3 × 0.3 mm grew within 4 days. The crystals belong to the space group P212121 with cell constants a = 50.0 Å, b = 57.8 Å, c = 74.3 Å and contain 1 elastase molecule per asymmetic unit. Crystals of the complex were soaked in a freezing solution consisting of 25% glycerol and 75% well solution (v/v) for approximately 5 s and then flash frozen by immersing in liquid nitrogen.

X-ray data for the EI116-elastase crystal complex were collected at 100 K using a MAR300 image plate mounted on an Enraf Nonius rotating anode generator operating at 40 kV and 80 mA to a resolution of 1.8 Å. Data collection statistics are given in Table I. X-ray data for the JD261-elastase complex were collected on station 7.2 at the Daresbury synchrotron source using a MAR 300 image plate to a resolution of 1.6 Å (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Data collection and refinement statistics

The structures were solved with the molecular replacement program AMoRe (10) using the model of porcine pancreatic elastase from a published crystal structure (entry 8EST in the Brookhaven Protein Data Base). All water and ligand molecules were removed from the model structure. Initial difference Fourier maps using phases calculated from the molecular replacement solutions showed clear electron density for both ligands. Subsequent refinement of all atom positions and individual isotropic thermal parameters was carried out using SHELX-97 (11) (Table I). A total of 282 water molecules were added to JD261 and 275 to EI116 using the program SHELXWAT (11). Both structures contained a calcium and a sulfate ion as described in other published structures. Despite the short (5 s) soaking time in the cryoprotectant solution, a well ordered glycerol molecule was located in the JD261-elastase complex. Rounds of conjugate gradient least squares refinement were alternated with examination of sigma weighted (2F(obs) - F(calc)) Fourier maps. This, along with the excellent quality high resolution data, ensured that any model bias was minimized. Once the R-factor had refined to a value of less than 0.18 using all data, hydrogen atoms were added in calculated positions. This reduced both the R-factor and the free R-factor for both structures by more than 1% leading to final R-factors of 0.16 with excellent geometries (Table I). Coordinates of both structures have been deposited in the Brookhaven Protein Data bank.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Geometry of JD261 and Interactions with the PPE Active Site-- The ligand was clearly visible in an initial electron density difference map. The excellent quality of the electron density calculated with data to a resolution of 1.60 Å shows that the ligand derived from JD261 is planar between the ester carbon attached to the serine and the nitrogen preceding the naphthalene ring system (Fig. 2). Furthermore, there is no trace of substituents on positions 3 and 4 of the beta -lactam. These observations are consistent with the structures and mechanism shown in Fig. 1a.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 2.   A difference electron density map calculated with sigma weighted (2Fo - Fc) coefficients and contoured at 1.5sigma showing the product of JD261 complexed with PPE. Carbon atoms for the inhibitor and protein are magenta and white, respectively. Oxygen atoms are red, and nitrogen atoms are blue.

The amide nitrogen atoms from Gly-201(193)2 and Ser-203(195) act as hydrogen bond donors to the ester carbonyl oxygen atom, which lies in the oxyanion pocket. (Table II and Fig. 3). The planar all trans configuration of JD261 places constraints upon the orientation of the urea moiety and only one other direct hydrogen bond can be formed between the urea oxygen atom and Gln-200(192) (Fig. 3). The urea nitrogen (N-1) is hydrogen bonded to a water molecule that forms a bridging hydrogen bond to the amide nitrogen of Val-224(216). The active site His-60(57) does not make any direct hydrogen bonds with JD261 but does form a hydrogen bond to W751 (Nepsilon -2 ... W = 2.7Å). This water molecule is only 3.3 Å from the carbon of the ester carbonyl and is well positioned to carry out a nucleophilic attack along the Burgi-Dunitz trajectory (Fig. 3).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Hydrogen bond distances as illustrated in Figs. 3 and 4


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   A stereo picture of the x-ray structure of the product of JD261 complexed with PPE using the program MOLSCRIPT (30). Carbon atoms for the inhibitor and protein are green and black, respectively. Oxygen atoms are red, and nitrogen atoms are blue. Hydrogen bonds are drawn as dashed red lines. Water molecules are shown as red spheres. The Burgi-Dunitz trajectory between W751 and C-1 is drawn as a yellow dashed line. (W751 ... C-1 = 3.3 Å, W751-(C-1)-O = 95o.)

Geometry of EI116 and Interactions with the PPE Active Site-- The EI116 ligand product was clearly visible in an initial electron density difference map and showed the presence of both ethyl groups on C-3. The refined structure also showed clearly that position 4 is tetrahedral with a 1 atom substituent, consistent with the mechanism shown in Fig. 1b.

There are three hydrogen bonds linking the ligand directly to the protein (Table II and Fig. 4). The beta -lactam carbonyl group of the EI116 complex occupies almost the same position in the oxyanion pocket as in JD261 and makes the same hydrogen bonds. The Nepsilon -2 atom from His-60(57) acts as a hydrogen bond donor to the hydroxyl oxygen atom bonded to C(4). Additionally this hydroxyl group forms an intramolecular hydrogen bond to Ogamma of the active site serine. Binding of the ligand is also stabilized by van der Waals interactions with Ser-222(214) and Phe-223(215) in binding pocket S2, with Val-224(216) and Gln-200(192) in binding pocket S3 and by a stacking interaction of the aromatic ring with the guanidinium group of Arg-226(217A) in binding pocket S4.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   A stereo picture of the refined x-ray structure of EI116 drawn with the same protein orientation as Fig. 3 drawn using MOLSCRIPT (30). Ligand carbon atoms are green, the bromine atom is orange, water molecules and oxygen atoms are red, and main-chain carbon atoms are black. Hydrogen bonds are drawn as dashed red lines. EI116 shows a hydrogen bonded chain of water molecules incorporating the hydroxy group on C-4 that is hydrogen bonded to His-60(57). Note the similarity of hydrogen bonding in the oxyanion hole between EI116 and JD261 (Fig. 3). Gln-200 adopts a different conformation in the two structures.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mechanism of beta -Lactam Inhibition-- The x-ray structures of the complexes are consistent with the mechanisms outlined in Fig. 1. The mechanism shown for the reaction of EI116 with elastase is similar to that proposed for a related series of compounds binding human leukocyte elastase (12). In that work, mass spectrometry and NMR were used to show acylation of the Ser-203(195), loss of the substituent on C-4 of the lactam ring, and subsequent formation of the carbinolamine. We can now show that the addition of water to the intermediate imine results in a carbon with (S) configuration as predicted by modeling studies (12). This hydroxyl group forms a hydrogen bond to His-60(57) and may play a role in the reactivation mechanism. Indeed this hydroxyl group may be derived from the hydrolytic water molecule that is required for deacylation and hence reactivation of elastase.

The new mechanism revealed by the binding of JD261 to elastase involves initial acylation of Ser-203(195) followed by loss of the OAr group from C-4. Thereafter, the hydroxyethyl substituent on C-3 provides an alternative pathway for reaction by a retro-aldol reaction to generate the acyl-enzyme intermediate with the concomitant release of acetaldehyde. This results in the planar conjugated intermediate shown in Fig. 1 and as a consequence there is no possibility of addition of water to C-4. The identity of the acylated enzyme complexes have both been verified using electrospray ionization mass spectrometry, and the masses of these covalent intermediates correspond to the major molecular species.

Comparison of Binding Modes of EI116 and JD261 with Peptide Analogue Compounds-- Atomic coordinates are available for 26 PPE x-ray structures. Protein inhibitor·PPE complexes include those with elafin (13), chymotrypsin elastase inhibitor(14), and a heptamer from beta -casomorphin-7 (15). Small molecule inhibitor complexes include: peptidyl fluoromethyl ketones (16-19), peptidyl chloromethyl ketones (20), peptidyl boronic acids (21), isocoumarin derivatives (22-24), peptidylketobenzoxazoles (25), and a peptidomimetic aminimide (26). In all cases the elastase active site maintains the same shape, and typical root mean square differences between backbone atoms are less than 0.3 Å. The side chains Gln-200(192) and Arg-226(217A) can adopt different conformations and these changes are particularly pronounced in the complex with JD261 where a very different conformation of the Gln-200(192) is required to make way for the naphthyl group of the ligand (Figs. 3 and 4). The unique placement of this ligand compared with all other published classes of inhibitor gives an indication of the relative lack of flexibility caused by its all-trans configuration and charge delocalized structure. The x-ray structure of trifluoroacetyl-Lys-Phe-p-isopropylanilide/PPE defined a new subsite for the anilide group, which was located under the side chain of Gln-200(192) (19). One ring of the naphthyl group of JD261 partly overlaps this site; however, the uniquely different conformation of Gln-200(192) in this structure provides a rather differently shaped pocket.

The position of EI116 in the active site resembles the binding adopted by other peptide-type inhibitors (16) in which the peptide side chains fill the specificity pockets S1 to S4. The closest similarity occurs with the trifluoroacetyl dipeptidyl isopropylanilide family of inhibitors (18). The S1 pocket is filled in this family by the trifluoroacetyl group, whereas EI116 fills the S1 pocket quite efficiently with one of the ethyl groups on what was C-3 of the beta -lactam. The S4 subsite accommodates the aromatic anilide group, which lies in the same place as the bromphenyl group of EI116. The presence of the aromatic group causes a significant shift in the position of the side chain of Arg-226(217A), which forms van der Waals contacts with the group.

The main-chain structures of elastase bound to EI116 and JD261 show an unexpected conformational difference from residues Asn-99(95)-Thr-100(96)-Asp-101(97)-Asp-102(98). All 26 available published x-ray structures of PPE complexes show these residues in a type I beta -turn. The electron density in the EI116 complex clearly shows a beta II turn despite the fact that there are no direct interactions with the ligand that may have induced the change.

Implications of Structure for Reactivation-- It has been shown that reactivation of human leukocyte elastase-inhibitor complexes, of a series of substituted mono-beta -lactams, results in a half-life of between 3 and 15 h. Stability of the complex is insensitive to increasing ionic strength and also to the nature of the leaving group on C-4 but does however depend on the nature of the substituted urea (1).

An unmodified heptapeptide complexed with elastase (15) has been found to form an acyl-complex with Ser-203(195) through the C-terminal carboxy group. The x-ray crystal structure of this complex shows the presence of a water molecule hydrogen bonded to Nepsilon -2 of His-60(57) and in an ideal position to attack the carbon of the ester carbonyl. A mechanism has been proposed that explains the cleavage of the acyl-enzyme intermediate by a hydroxide ion that is derived by deprotonation of a water molecule by His-60(57) (15). The structure of the JD216 complex has an identically positioned water molecule. However, the presence of the conjugated double bond is likely to confer hydrolytic stability on the acyl-enzyme intermediate as has been previously noted by the inhibition of beta -lactamase by clavulanic acid (27-29). JD261 is therefore an example of a new class of serine protease inhibitor that provides a novel chemical mechanism for resisting reactivation. We are currently exploring the generality of this mechanism with proteases other than elastase.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. E-mail: m.walkinshaw@ed.ac.uk.

2 The numbering nomenclature for PPE is taken from Mattos et al. (18) in which amino acid residues of PPE are numbered sequentially beginning with Val-16(16) and ending with Asn-255(245). In this scheme, residues of the catalytic triad are Ser-203(195), His-60(57), Asp-108(102).

    ABBREVIATIONS

The abbreviation used is: PPE, porcine pancreatic elastase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Green, B. G., Chabin, R., Mills, S., Underwood, D. J., Shah, S. K., Kuo, D., Gale, P., Maycock, A. L., Liesch, J., Burgey, C. S., Doherty, J. B., Dorn, C. P., Finke, P. E., Hagmann, W. K., Hale, J. J., Maccoss, M., Westler, W. M., and Knight, W. B. (1995) Biochemistry 34, 14331-14343[CrossRef][Medline] [Order article via Infotrieve]
2. Strynadka, N. C. J., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K., and James, M. N. G. (1992) Nature 359, 700-705[CrossRef][Medline] [Order article via Infotrieve]
3. Tew, D. G., Boyd, H. F., Ashman, S., Theobald, C., and Leach, C. A. (1998) Biochemistry 37, 10087-10093[CrossRef][Medline] [Order article via Infotrieve]
4. Paetzel, M., Dalbey, R. E., and Strynadka, N. C. J. (1998) Nature 396, 186-190[CrossRef][Medline] [Order article via Infotrieve]
5. Kerrigan, J. E., Oleksyszyn, J., Kam, C. M., Selzler, J., and Powers, J. C. (1995) J. Med. Chem. 38, 544-552[CrossRef][Medline] [Order article via Infotrieve]
6. Birrer, P., Mcelvaney, N. G., Rudeberg, A., Sommer, C. W., Liechtigallati, S., Kraemer, R., Hubbard, R., and Crystal, R. G. (1994) Am. J. Respir. Crit. Care Med. 150, 207-213[Abstract]
7. Janusz, M. J., and Durham, S. L. (1997) Inflamm. Res. 46, 503-508[CrossRef][Medline] [Order article via Infotrieve]
8. Navia, M. A., Springer, J. P., Lin, T. Y., Williams, H. R., Firestone, R. A., Pisano, J. M., Doherty, J. B., Finke, P. E., and Hoogsteen, K. (1987) Nature 327, 79-82[CrossRef][Medline] [Order article via Infotrieve]
9. Wilmouth, R. C., Westwood, N. J., Anderson, K., Brownlee, W., Claridge, T. D. W., Clifton, I. J., Pritchard, G. J., Aplin, R. T., and Schofield, C. J. (1998) Biochemistry 37, 17506-17513[CrossRef][Medline] [Order article via Infotrieve]
10. Navaza, J. (1994) Acta Crystallogr. Sect. A 50, 157-163[CrossRef]
11. Sheldrick, G. M. (1997) SHELX-97 University of Goettingen, Germany
12. Underwood, D. J., Green, B. G., Chabin, R., Mills, S., Doherty, J. B., Finke, P. E., Maccoss, M., Shah, S. K., Burgey, C. S., Dickinson, T. A., Griffin, P. R., Lee, T. E., Swiderek, K. M., Covey, T., Westler, W. M., and Knight, W. B. (1995) Biochemistry 34, 14344-14355[CrossRef][Medline] [Order article via Infotrieve]
13. Tsunemi, M., Matsuura, Y., Sakakibara, S., and Katsube, Y. (1996) Biochemistry 35, 11570-11576[CrossRef][Medline] [Order article via Infotrieve]
14. Huang, K., Strynadka, N. C. J., Bernard, V. D., Peanasky, R. J., and James, M. N. G. (1994) Structure 2, 679-689[Medline] [Order article via Infotrieve]
15. Wilmouth, R. C., Clifton, I. J., Robinson, C. V., Roach, P. L., Aplin, R. T., Westwood, N. J., Hajdu, J., and Schofield, C. J. (1997) Nat. Struct. Biol. 4, 456-462[CrossRef][Medline] [Order article via Infotrieve]
16. Bode, W., Meyer, E., and Powers, J. C. (1989) Biochemistry 28, 1951-1963[CrossRef][Medline] [Order article via Infotrieve]
17. Takahashi, L. H., Radhakrishnan, R., Rosenfield, R. E., Meyer, E. F., Trainor, D. A., and Stein, M. (1988) J. Mol. Biol. 201, 423-428[CrossRef][Medline] [Order article via Infotrieve]
18. Mattos, C., Giammona, D. A., Petsko, G. A., and Ringe, D. (1995) Biochemistry 34, 3193-3203[CrossRef][Medline] [Order article via Infotrieve]
19. Mattos, C., Rasmussen, B., Ding, X. C., Petsko, G. A., and Ringe, D. (1994) Nat. Struct. Biol. 1, 55-58[CrossRef][Medline] [Order article via Infotrieve]
20. Wei, A. Z., Mayr, I., and Bode, W. (1988) FEBS Lett. 234, 367-373[CrossRef][Medline] [Order article via Infotrieve]
21. Takahashi, L. H., Radhakrishnan, R., Rosenfield, R. E., and Meyer, E. F. (1989) Biochemistry 28, 7610-7617[CrossRef][Medline] [Order article via Infotrieve]
22. Powers, J. C., Oleksyszyn, J., Narasimhan, S. L., Kam, C. M., Radhakrishnan, R., and Meyer, E. F. (1990) Biochemistry 29, 3108-3118[CrossRef][Medline] [Order article via Infotrieve]
23. Vijayalakshmi, J., Meyer, E. F., Kam, C. M., and Powers, J. C. (1991) Biochemistry 30, 2175-2183[CrossRef][Medline] [Order article via Infotrieve]
24. Hernandez, M. A., Powers, J. C., Glinski, J., Oleksyszyn, J., Vijayalakshmi, J., and Meyer, E. F. (1992) J. Med. Chem. 35, 1121-1129[CrossRef][Medline] [Order article via Infotrieve]
25. Edwards, P. D., Meyer, E. F., Vijayalakshmi, J., Tuthill, P. A., Andisik, D. A., Gomes, B., and Strimpler, A. (1992) J. Am. Chem. Soc. 114, 1854-1863[CrossRef]
26. Peisach, E., Casebier, D., Gallion, S. L., Furth, P., Petsko, G. A., Hogan, J. C., and Ringe, D. (1995) Science 269, 66-69[Abstract/Free Full Text]
27. Knowles, J. R. (1985) Acc. Chem. Res. 18, 97-104
28. Chen, C. C. H., and Herzberg, O. (1992) J. Mol. Biol. 224, 1103-1113[CrossRef][Medline] [Order article via Infotrieve]
29. Brown, R. P. A., Aplin, R. T., and Schofield, C. J. (1996) Biochemistry 35, 12421-12432[CrossRef][Medline] [Order article via Infotrieve]
30. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950 [CrossRef]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
I. Dell'Aica, L. Sartor, P. Galletti, D. Giacomini, A. Quintavalla, F. Calabrese, C. Giacometti, E. Brunetta, F. Piazza, C. Agostini, et al.
Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-beta-lactam with a Galloyl Moiety
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 539 - 546.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Kulanthaivel, A. J. Kreuzman, M. A. Strege, M. D. Belvo, T. A. Smitka, M. Clemens, J. R. Swartling, K. L. Minton, F. Zheng, E. L. Angleton, et al.
Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I
J. Biol. Chem., August 27, 2004; 279(35): 36250 - 36258.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, P.
Right arrow Articles by Walkinshaw, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, P.
Right arrow Articles by Walkinshaw, M. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.